This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Aggarwal C , Somaiah N , Simon GR
Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time?
J Natl Compr Canc Netw. 2010 Jul;8(7) :822-32
AbstractLung cancer is the leading cause of cancer-related mortality in the United States. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Most patients with NSCLC present with locoregionally advanced or metastatic disease, for which response rates and median overall survival remain poor. Platinum-based chemotherapy is the mainstay of treatment for NSCLC in both adjuvant and metastatic disease. Personalized chemotherapy and targeted biologic therapy based on a tumor's histologic and molecular profile have already shown promise in optimizing efficacy. Various markers are currently being investigated for their ability to guide treatment decision-making and management. This article describes these predictive and prognostic markers and details their current role, benefit, and potential future use in the management of patients with NSCLC.
NotesAggarwal, Charu Somaiah, Neeta Simon, George R United States Journal of the National Comprehensive Cancer Network : JNCCN J Natl Compr Canc Netw. 2010 Jul;8(7):822-32.